drugset / Trial / NCT00042406
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether HuMax-CD4 is effective in the treatment of active RA in participants who have failed treatment with MTX and at least one TNF-alpha blocking agent.
Timeline
- Start
- 2002-03-04
- Primary completion
- 2003-03-31
- Completion
- 2003-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanolimumab | Monoclonal antibody | 80 mg | Subcutaneous |
| Subject | Zanolimumab | Monoclonal antibody | 160 mg | Subcutaneous |